These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Thaçi D; Ortonne JP; Chimenti S; Ghislain PD; Arenberger P; Kragballe K; Saurat JH; Khemis A; Sprøgel P; Esslinger HU; Unnebrink K; Kupper H Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585 [TBL] [Abstract][Full Text] [Related]
3. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499 [TBL] [Abstract][Full Text] [Related]
4. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Chew AL; Bennett A; Smith CH; Barker J; Kirkham B Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561 [TBL] [Abstract][Full Text] [Related]
5. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Ryan C; Kirby B; Collins P; Rogers S Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535 [TBL] [Abstract][Full Text] [Related]
6. An update on topical therapies for mild-moderate psoriasis. van de Kerkhof PC Dermatol Clin; 2015 Jan; 33(1):73-7. PubMed ID: 25412784 [TBL] [Abstract][Full Text] [Related]
7. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299 [TBL] [Abstract][Full Text] [Related]
8. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631 [TBL] [Abstract][Full Text] [Related]
10. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543 [TBL] [Abstract][Full Text] [Related]
11. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044 [TBL] [Abstract][Full Text] [Related]
13. Marked improvement in nail psoriasis during treatment with adalimumab. Irla N; Yawalkar N Dermatology; 2009; 219(4):353-6. PubMed ID: 19851059 [TBL] [Abstract][Full Text] [Related]
14. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital. Noda S; Mizuno K; Adachi M J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280 [TBL] [Abstract][Full Text] [Related]
16. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264 [TBL] [Abstract][Full Text] [Related]
17. New developments in topical sequential therapy for psoriasis. Koo JY Skin Therapy Lett; 2005 Nov; 10(9):1-4. PubMed ID: 16292458 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254 [TBL] [Abstract][Full Text] [Related]
19. Case presentation of moderate-severe psoriasis. Salmhofer W J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():19-20. PubMed ID: 22758914 [TBL] [Abstract][Full Text] [Related]
20. Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy. Gutiérrez-González E; Batalla A; de la Mano D Dermatol Online J; 2014 Apr; 20(4):22338. PubMed ID: 24746301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]